Cytrellis Completes $28.5 Million Series B Financing
Cytrellis announced today that it has received $28.5 million in a Series B round which included existing investors ARCH Venture Partners, the Merz Venture Initiative and new investors, Partner Fund Management and BioMatics Captial.
Cytrellis Clinical Results Recently Presented at 2018 ASLMS Conference
Dallas, TX –
Dr. Roy Geronemus, director of the Laser & Skin Surgery Center of New York, recently presented findings from Cytrellis’ multi-center study of 23 women who were treated bilaterally in the mid and lower face, using Cytrellis’ proprietary device.
Merz Pharma announces new investment in Cytrellis Biosystems
Frankfurt am Main, Germany and Boston, MA
Merz Pharma has made a strategic investment in Cytrellis Biosystems, a US based company developing a new class of non-surgical products to combat sagging skin associated with aging.
Welcome to Cytrellis
Welcome to Cytrellis’ new and improved website! We are excited to announce the launch of our new web site which now includes new sections and additional info. You can now find more general information about the company, the latest news about Cytrellis’ technology as well as explore career opportunities.